<DOC>
	<DOC>NCT01586364</DOC>
	<brief_summary>The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus.</brief_summary>
	<brief_title>Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal women aged 40 to 80 years with a diagnosis of vulvar and vaginal atrophy (VVA) as assessed by vaginal pH, maturation index of vaginal smear, and selfreported symptoms at Baseline for Protocol 1550310 Did not have a uterus Met the inclusion and exclusion criteria for Protocol 1550310 Had completed Protocol 1550310 without any clinically significant abnormal findings at the endofstudy visit for Protocol 1550310 Provided written informed consent to participate in the study and agreed to follow dosing instructions and complete all required study visits Had clinically significant abnormal findings at the Week 12 End of Study visit for Protocol 1550310 Had any physical or mental condition which, in the opinion of the investigator, may have interfered with the subject's ability to comply with the study procedures</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Menopausal symptoms</keyword>
	<keyword>Vulvar and vaginal atrophy in menopausal women</keyword>
	<keyword>Vaginal atrophy</keyword>
	<keyword>Urogenital atrophy</keyword>
</DOC>